TY - JOUR AU - Darrigues, Lauren AU - Pierga, Jean-Yves AU - Bernard-Tessier, Alice AU - Bièche, Ivan AU - Silveira, Amanda Bartolini AU - Michel, Marc AU - Loirat, Delphine AU - Cottu, Paul AU - Cabel, Luc AU - Dubot, Coraline AU - Geiss, Romain AU - Ricci, Francesco AU - Vincent-Salomon, Anne AU - Proudhon, Charlotte AU - Bidard, François-Clément PY - 2021 DA - 2021/03/06 TI - Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients JO - Breast Cancer Research SP - 31 VL - 23 IS - 1 AB - Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard therapy in women with estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). Palbociclib has been shown to increase the progression-free survival (PFS) overall but no predictive biomarker of palbociclib efficacy has been validated so far. We thus evaluated whether early changes of circulating tumor DNA (ctDNA) levels are associated with palbociclib plus fulvestrant efficiency. SN - 1465-542X UR - https://doi.org/10.1186/s13058-021-01411-0 DO - 10.1186/s13058-021-01411-0 ID - Darrigues2021 ER -